Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Topical Immunotherapy With Diphenylcyclopropenone in Paediatric Patients With Alopecia Areata—A Retrospective Study of 97 Patients Publisher



Esmaeili F1 ; Vahabi SM2 ; Abdoli M2 ; Fazeli P3 ; Ghandi N2 ; Seddigh L4 ; Aryanian Z2 ; Etesami I2
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Division of Biology & Medicine, Brown University, Providence, RI, United States
  4. 4. Department of Community Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Skin Health and Disease Published:2024


Abstract

Background: Alopecia areata (AA) is an autoimmune disease causing chronic non-scarring hair loss. Different therapeutic regimens have been suggested for AA, which depend on patients' age, scalp involvement extent and duration. Topical immunotherapy with diphenylcyclopropenone (DPCP) is one of the treatment options for these patients. Objectives: We aimed to investigate the response to DPCP in paediatric AA patients. Methods: This retrospective study included 97 paediatric AA patients followed in the DPCP clinic from March 2016 to March 2021 at a referral dermatology hospital. Results: In a cohort of 97 paediatric patients with AA under treatment with DPCP, with a mean age of 11.10 ± 0.9, 53.6% of the patients were male. Patchy alopecia was the most prevalent type (45.4%). After 6 months of DPCP treatment, 51.5% showed no response, while 3.1% achieved complete response. At the 12-month evaluation, among the 68 patients who continued treatment, complete response was observed in 8.8%. A significant positive correlation was found between alopecia type, specifically patchy, and treatment response (p = 0.031). Additionally, treatment duration emerged as a significant predictor of positive response at both six (OR 1.450, p = 0.026) and 12 months (OR 1.310, p = 0.043). A higher initial Severity of Alopecia Tool score was inversely correlated with treatment response (Spearman's rho −0.14, p = 0.002), indicating that initial disease severity may predict treatment efficacy. Conclusions: One year after the onset of DPCP in paediatric AA patients, the complete response and any hair regrowth rates were 8.8% and 61.8%, respectively. The milder initial disease severity and longer duration of treatment resulted in a better response. © 2024 The Author(s). Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Related Docs
1. Is the Severity of Initial Sensitization to Diphenylcyclopropenone in Alopecia Areata Patients Predictive of the Final Clinical Response?, Dermatologic Therapy (2021)
2. Utility of Dermoscopic Evaluation in Predicting Clinical Response to Diphencyprone in a Cohort of Patients With Alopecia Areata, International Journal of Trichology (2020)
3. Alopecia Areata: A Review of Disease Pathogenesis, British Journal of Dermatology (2018)
4. Treatment Satisfaction and Response in Patients With Severe Alopecia Areata Under Treatment With Diphenylcyclopropenone, Health Science Reports (2022)
5. A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata, International Immunopharmacology (2021)
6. Topical Immunotherapy With Diphenylcyclopropenone in Patients With Alopecia Areata: A Large Retrospective Study of 757 Patients, Dermatologic Therapy (2020)
7. Clinical and Demographic Characteristics Associated With Nail Involvement in Alopecia Areata: A Cross-Sectional Study of 197 Patients, Health Science Reports (2024)
Experts (# of related papers)
View all Related Experts
Narges Ghandi (6)
Robabeh Abedini (5)